US Maintains Pressure on India's Pharmaceutical Patent System Through Priority Watch List Designation
核心洞察
India remains on the US Trade Representative's Priority Watch List for 2026, continuing a designation held since the 1990s due to disputes over pharmaceutical intellectual property protections.
The US specifically targets India's Section 3(d) (搜索) patent provision that prevents evergreening, compulsory licensing rules, and absence of data exclusivity for clinical trial data.
India's generic pharmaceutical industry supplies nearly 20% of global generic medicines (搜索), with generics typically reducing drug prices by 80-90% compared to branded alternatives.
The United States has once again placed India on its Priority Watch List in the 2026 Special 301 Report, maintaining pressure on New Delhi's pharmaceutical patent regime that has been a source of bilateral tension for over three decades. The Office of the US Trade Representative (搜索) (USTR) released the report on April 30, flagging concerns over intellectual property protection, data exclusivity gaps, and enforcement issues in India's pharmaceutical sector.
India has remained on this list since the 1990s, reflecting persistent disagreements between the two nations over pharmaceutical IP standards. While the designation carries no immediate legal consequences, experts describe it as an administrative pressure tool that often influences bilateral negotiations and future trade demands.
Core Areas of US Concern
The USTR report specifically targets several key provisions of India's patent framework. Section 3(d) (搜索) of India's patent law, which disallows patents on new forms of known drugs unless they demonstrate enhanced therapeutic efficacy, remains a primary flashpoint. This provision is designed to prevent "evergreening" - the practice of making minor modifications to extend patent life without meaningful therapeutic benefit.
The US has also questioned India's compulsory licensing rules, expressing concerns about regulatory uncertainty. Under these provisions, the government can permit third parties to produce patented products without patent holder consent under specific public interest conditions. However, India maintains that such licensing has been extremely limited and carefully regulated.
Data exclusivity represents another major area of contention. The absence of statutory protection for clinical trial data allows generic manufacturers to rely on originator data, while the US typically seeks at least five years of exclusivity for small molecules and up to 12 years for biologics.
India's Defense of Its System
India maintains that its patent regime is fully compliant with World Trade Organization rules and designed to prevent patent misuse rather than stifle genuine innovation. The country's framework under the Patents Act, 1970 prioritizes public health objectives while ensuring access to affordable medicines.
The Global Trade Research Initiative (搜索) (GTRI) noted that past cases demonstrate how this balance has functioned in practice. In the landmark Novartis case, India's Supreme Court rejected a patent for a modified cancer drug (搜索), enabling the production of significantly cheaper generics. Similarly, a compulsory license granted in a Bayer (搜索) case sharply reduced the price of a life-saving treatment while ensuring royalties to the innovator.
Global Impact of India's Generic Industry
India's pharmaceutical sector plays a crucial role in global healthcare access, supplying nearly 20% of the world's generic medicines (搜索). These generics typically reduce drug prices by 80-90% compared to branded alternatives, making essential treatments accessible to patients worldwide, including in the United States.
The country exported $9.7 billion worth of medicines to the US in 2025, primarily low-cost generics that help reduce American healthcare costs. This positions India as what industry observers call the "pharmacy of the world."
Enforcement and Additional Concerns
Beyond patent law provisions, the USTR report highlights enforcement gaps including piracy, counterfeiting, and judicial delays. Additional concerns include the absence of a dedicated trade secrets law, drug price controls, and delays in patent processing.
India's position is that trade secrets receive adequate protection through contracts and common law, while price controls remain necessary to ensure medication affordability. The country is working to streamline patent procedures to address processing delays.
Future Implications
The GTRI cautioned that accepting US demands could significantly weaken India's generics industry and harm patients globally, including those in the United States. The think tank emphasized that India should avoid diluting key patent law provisions such as Section 3(d) (搜索) and compulsory licensing under external pressure.
As India negotiates new trade agreements, pressure to recalibrate its IP regime is likely to intensify. The continued Priority Watch List designation signals that this long-running dispute will remain a focal point in US-India trade relations, with implications extending far beyond bilateral commerce to global healthcare access and affordability.